|
시장보고서
상품코드
2070523
보체 억제제 시장 : 규모, 점유율, 성장, 세계 업계 분석, 지역별 동향 및 예측(2026-2034년)Complement Inhibitors Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
보체 억제제 시장의 성장 요인
세계 보체 억제제 시장은 2025년에 90억 달러 규모로 평가되었습니다. 2026년 103억 달러에서 2034년까지 324억 달러로 성장하여, 예측 기간 동안 연평균 성장률(CAGR)은 15.40%에 이를 것으로 전망됩니다. 2025년에는 희귀질환 진단 기술의 발전, 고품질 전문 치료법의 도입, 규제 당국의 승인, 그리고 첨단 의료 인프라에 힘입어 북미가 56.44%의 점유율로 시장을 독점했습니다.
보체 억제제는 보체 면역 경로의 특정 부분을 억제하는 표적 치료법입니다. 이 약들은 발작성 야간 혈색소뇨증, 비정형 용혈성 요독 증후군, 전신성 중증 근무력증, 지도상 위축, C3 사구체증, 기타 면역매개성 질환 등의 희귀질환 및 만성 질환 치료에 사용되고 있습니다.
시장 동향
시장의 주요 동향으로는 보체 억제제의 적응증이 더 광범위한 질환으로 확대되고 있다는 점을 들 수 있습니다. 초기에는 주로 PNH나 aHUS와 같은 희귀 혈액 질환에 사용이 집중되어 있었습니다. 그러나 현재 각 제약사는 이러한 약물의 적응증을 신장 질환, 신경계 질환, 안과 질환 및 면역매개성 질환으로 확대되고 있습니다.
이러한 변화로 인해 의사의 인지도가 높아지고, 치료 대상이 되는 환자층이 확대되며, 파이프라인에 대한 투자가 촉진되고 있습니다. 예를 들어, 노바티스의 ‘파브할타’가 C3 사구체증 적응증으로 승인된 것은 신장 질환에서 보체 억제의 역할이 확대되고 있음을 여실히 보여주고 있습니다.
시장 성장 촉진요인
주요 촉진요인은 희귀질환 및 만성질환 전반에 걸쳐 보체를 표적으로 하는 치료법의 승인 건수가 증가하고 있다는 점입니다. 규제 당국의 승인을 성공적으로 획득하면 의사의 신뢰를 높이고, 제품의 신뢰성을 강화하며, 기업이 더 많은 환자층에 접근할 수 있게 됩니다.
C5, C3, 인자 B, 인자 D 및 C1s를 표적으로 하는 새로운 치료법의 승인으로 치료 선택지가 확대되고 있습니다.월1회 피하 투여 등 투여의 편의성이 향상된 점도 환자들의 수용과 임상 현장에서의 보다 광범위한 도입을 뒷받침하고 있습니다.
시장 성장 억제요인
고액의 치료비와 보험 환급과 관련된 압박은 여전히 주요 제약 요인으로 작용하고 있습니다. 보체 억제제는 장기적 또는 평생에 걸친 치료로 사용되는 경우가 많아, 보험사 입장에서는 예산 부담이 커집니다. 그 결과, 보험사나 의료 제도는 엄격한 보험 급여 관리, 가치 평가 및 이용 제한을 적용할 가능성이 있습니다.
이로 인해 임상적 필요성이 높은 경우에도 치료 시작이 지연되거나 접근이 제한될 가능성이 있습니다.
시장 기회
여러 보체 표적을 아우르는 강력한 파이프라인 개발이 큰 기회를 창출하고 있습니다. 각 회사는 C5, C3, C1q, C1s, 팩터 B 및 팩터 D를 표적으로 하는 치료제를 개발하고 있으며, 신장학, 신경학, 안과, 혈액학 및 자가면역질환 분야에서 새로운 가능성을 열어가고 있습니다.
이러한 표적의 다양화를 통해 단일 작용기전에 대한 의존도를 낮추고, 차별화된 제품 개발을 촉진할 수 있습니다. 새로운 파이프라인 후보는 시장을 좁은 희귀질환 부문에서 보다 광범위한 전문 의료 분야로 전환하는 데 기여할 가능성이 있습니다.
시장의 과제
지역을 불문하고, 규정을 준수하고 제조 품질을 유지하는 것은 중요한 과제입니다. 보체 억제제는 엄격한 품질 관리, 안전성 모니터링, 표시 및 승인 기준이 요구되는 복잡한 전문 의약품입니다. 규정 준수 문제가 발생하면, 지연, 리콜, 비용 증가 또는 공급 중단으로 이어질 가능성이 있습니다.
또한, 고도의 임상 모니터링 요건, 안전성 관리 및 접근 관리 역시 제조업체와 의료 서비스 제공업체에게 운영상의 부담이 되고 있습니다.
세분화 분석
약제별로 보면, 시장에는 에크리주맙, 라브리주맙, 페그세타코플란, 이프타코판, 스팀리맙, 아바신카프타드·페골 등이 포함됩니다. 라브리즈마브는 강력한 임상적 효능, 투여 간격 연장, 그리고 보체 매개 질환 전반에 걸친 적용 범위의 확대를 통해 2025년에는 시장을 휩쓸었습니다. '기타' 부문은 연평균 성장률(CAGR) 28.67%를 나타낼 것으로 예측됩니다.
질환별 적응증으로는 시장에 PNH, aHUS, 전신성 중증 근력 약화증, 시신경척수염 스펙트럼 장애, 지리적 위축, 냉응집증 등이 포함됩니다. 2025년에는 조기 승인, 확립된 임상적 사용, 그리고 고품질 보체 요법에 대한 지속적인 수요로 인해 PNH가 시장을 장악했습니다. '기타' 부문은 연평균 성장률(CAGR) 30.82%로 성장할 것으로 전망됩니다.
연령대별로는 시장 세분화에 따라 소아와 성인으로 구분됩니다. 성인 부문은 승인 범위의 확대, 치료 대상 환자 수가 많다는 점, 그리고 처방에 대한 익숙함 등을 이유로 2025년에는 시장을 주도했습니다. 소아 부문은 연평균 성장률(CAGR) 16.10%를 나타낼 것으로 예측됩니다.
유형별로 보면, 시장은 브랜드 제품, 바이오시밀러, 기타로 분류됩니다. 2025년에는 명확한 임상적 차별화, 희귀질환 치료제로서의 입지, 전문의 대상 교육, 그리고 프리미엄 가격 책정을 통해 브랜드 제품이 시장을 독점했습니다. 바이오시밀러 부문은 연평균 성장률(CAGR) 32.39%로 성장할 것으로 전망됩니다.
대상 경로별로는 2025년에 C5 억제제가 초기 임상적 유효성 입증과 규제 당국의 승인을 획득함에 따라 시장을 주도했습니다. 팩터 B 억제제 부문은 연평균 성장률(CAGR) 28.44%로 성장할 것으로 전망됩니다.
투여 경로별로 보면, 2025년에는 오리지널 의약품의 우위성, 투여 관리의 용이성, 그리고 병원 내 모니터링과 같은 요인들로 인해 정맥 내 투여 요법이 시장을 독점했습니다. 유리체 내 투여 부문은 연평균 성장률(CAGR) 23.57%를 나타낼 것으로 예측됩니다.
유통 채널별로는 고비용의 전문 치료제 사용, 백신 접종 프로토콜, 안전 요건, 전문의의 감독 하에 이루어지는 치료 등의 요인으로 인해 병원 약국이 시장을 주도했습니다. 온라인 약국 부문은 연평균 성장률(CAGR) 23.42%로 성장할 것으로 전망됩니다.
지역별 분석
북미는 2025년에 50억 8,000만 달러를 기록하며 시장을 주도했습니다. 미국 시장은 2026년에 53억 7,000만 달러로 추정되며, 전 세계 매출의 약 52.10%를 차지할 것으로 전망됩니다.
유럽은 신규 승인 및 치료 옵션 확대에 힘입어 2026년에는 24억 7,000만 달러에 달할 것으로 전망됩니다. 독일은 5억 5,000만 달러로 추산되는 반면, 영국은 2026년에 4억 9,000만 달러에 달할 것으로 전망됩니다.
아시아태평양의 규모는 2026년에 15억 2,000만 달러에 달할 것으로 추정됩니다. 중국은 5억 6,000만 달러, 일본은 3억 6,000만 달러, 인도는 1억 8,000만 달러에 달할 것으로 예측됩니다.
라틴아메리카는 3억 2,000만 달러로 추산되며, GCC 시장은 2026년에 7,000만 달러에 달할 것으로 예측됩니다. 남아프리카공화국의 규모는 2026년에 4,000만 달러에 달할 것으로 예측됩니다.
목차
제1장 서론
제2장 주요 요약
제3장 시장 역학
제4장 주요 인사이트
제5장 세계의 보체 억제제 시장 : 분석, 인사이트, 예측(2021-2034년)
제6장 북미의 보체 억제제 시장 : 분석, 인사이트, 예측(2021-2034년)
제7장 유럽의 보체 억제제 시장 : 분석, 인사이트, 예측(2021-2034년)
제8장 아시아태평양의 보체 억제제 시장 : 분석, 인사이트, 예측(2021-2034년)
제9장 라틴아메리카의 보체 억제제 시장 : 분석, 인사이트, 예측(2021-2034년)
제10장 중동 및 아프리카의 보체 억제제 시장 : 분석, 인사이트, 예측(2021-2034년)
제11장 경쟁 분석
KTHGrowth Factors of Complement Inhibitors Market
The global Complement Inhibitors Market was valued at USD 9.00 billion in 2025 and is projected to grow from USD 10.30 billion in 2026 to USD 32.40 billion by 2034, exhibiting a CAGR of 15.40% during the forecast period. North America dominated the market in 2025 with a 56.44% share, supported by strong rare-disease diagnosis, premium specialty therapy adoption, regulatory approvals, and advanced healthcare infrastructure.
Complement inhibitors are targeted therapies that block specific parts of the complement immune pathway. They are used in rare and chronic diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, geographic atrophy, C3 glomerulopathy, and other immune-mediated disorders.
Market Trends
A key trend in the market is the expansion of complement inhibitors into broader disease indications. Earlier use was mainly focused on rare blood disorders such as PNH and aHUS. However, companies are now expanding these drugs into renal, neurology, ophthalmology, and immune-mediated conditions.
This shift is increasing physician awareness, expanding patient eligibility, and encouraging pipeline investment. For example, Novartis' Fabhalta approval for C3 glomerulopathy highlights the growing role of complement inhibition in renal diseases.
Market Drivers
The main driver is the rising number of approvals for complement-targeted therapies across rare and chronic diseases. Regulatory success improves physician confidence, strengthens product credibility, and gives companies access to larger patient pools.
Approvals for newer therapies targeting C5, C3, Factor B, Factor D, and C1s are expanding treatment options. Improved dosing convenience, such as monthly subcutaneous therapy, is also supporting patient acceptance and wider clinical adoption.
Market Restraints
High treatment cost and reimbursement pressure remain major restraints. Complement inhibitors are often used as long-term or lifelong therapies, creating a high budget impact for payers. As a result, insurers and healthcare systems may apply strict reimbursement controls, value assessments, and access restrictions.
This can delay treatment initiation and reduce access, even when clinical need is high.
Market Opportunities
Strong pipeline development across multiple complement targets creates major opportunities. Companies are developing therapies against C5, C3, C1q, C1s, Factor B, and Factor D, opening new possibilities in nephrology, neurology, ophthalmology, hematology, and autoimmune diseases.
This target diversification can reduce dependence on single mechanisms and support differentiated product development. New pipeline candidates may help the market move from a narrow rare-disease segment toward a broader specialty-care opportunity.
Market Challenges
Maintaining regulatory compliance and manufacturing quality across regions is a key challenge. Complement inhibitors are complex specialty medicines requiring strict quality control, safety monitoring, labeling, and approval standards. Any compliance issue can lead to delays, recalls, higher costs, or supply disruptions.
High clinical monitoring requirements, safety controls, and access management also add operational pressure for manufacturers and healthcare providers.
Segmentation Analysis
By drug, the market includes eculizumab, ravulizumab, pegcetacoplan, iptacopan, sutimlimab, avacincaptad pegol, and others. Ravulizumab dominated the market in 2025 due to strong clinical efficacy, longer dosing intervals, and broad lifecycle expansion across complement-mediated diseases. The others segment is expected to grow at a CAGR of 28.67%.
By disease indication, the market includes PNH, aHUS, generalized myasthenia gravis, neuromyelitis optica spectrum disorder, geographic atrophy, cold agglutinin disease, and others. PNH dominated in 2025 due to early approval, established clinical use, and sustained demand for premium complement therapies. The others segment is projected to grow at a CAGR of 30.82%.
By age group, the market is segmented into pediatric and adults. The adult segment dominated in 2025 due to broader approvals, larger treated populations, and stronger prescribing familiarity. The pediatric segment is expected to grow at a CAGR of 16.10%.
By type, the market includes branded, biosimilar, and others. Branded therapies dominated in 2025 due to strong clinical differentiation, orphan positioning, specialist education, and premium pricing. The biosimilar segment is projected to grow at a CAGR of 32.39%.
By target pathway, C5 inhibitors led the market in 2025 due to early clinical validation and regulatory success. The Factor B inhibitors segment is projected to grow at a CAGR of 28.44%.
By route of administration, intravenous therapies dominated in 2025 due to first-mover advantage, controlled administration, and hospital-based monitoring. The intravitreal segment is expected to grow at a CAGR of 23.57%.
By distribution channel, hospital pharmacies led the market due to high-cost specialty therapy use, vaccination protocols, safety requirements, and specialist-supervised treatment. The online pharmacies segment is projected to grow at a CAGR of 23.42%.
Regional Analysis
North America led the market with USD 5.08 billion in 2025. The U.S. market is estimated at USD 5.37 billion in 2026, accounting for around 52.10% of global revenue.
Europe is projected to reach USD 2.47 billion in 2026, supported by newer approvals and broader treatment options. Germany is estimated at USD 0.55 billion, while the U.K. is expected to reach USD 0.49 billion in 2026.
Asia Pacific is estimated to reach USD 1.52 billion in 2026. China is projected at USD 0.56 billion, Japan at USD 0.36 billion, and India at USD 0.18 billion in 2026.
Latin America is estimated at USD 0.32 billion, while the GCC market is expected to reach USD 0.07 billion in 2026. South Africa is projected at USD 0.04 billion in 2026.
Competitive Landscape
Key companies include Alexion Pharmaceuticals, Novartis AG, F. Hoffmann-La Roche Ltd, Apellis Pharmaceuticals, UCB S.A., Amgen Inc., Regeneron Pharmaceuticals, Omeros Corporation, Annexon, and BioCryst Pharmaceuticals. These companies focus on new indications, regulatory approvals, pipeline development, partnerships, and product launches.
Key Industry Developments
In March 2026, Royalty Pharma entered a USD 500 million R&D co-funding agreement with Johnson & Johnson. In December 2025, Akebia established a rare kidney disease pipeline including ADX-097. In August 2025, AstraZeneca Pharma India announced the launch of Soliris in India. In June 2025, Sanofi received orphan drug designation for riliprubart in Japan. In September 2022, Asahi Kasei Pharma and Swedish Orphan Biovitrum collaborated on pegcetacoplan in Japan.
Conclusion
The global complement inhibitors market is expected to grow from USD 9.00 billion in 2025 to USD 10.30 billion in 2026 and reach USD 32.40 billion by 2034. Growth will be driven by new approvals, expanded indications, strong rare-disease demand, and innovation across complement targets. Despite high therapy costs and reimbursement challenges, pipeline expansion and broader use in renal, neurological, ophthalmic, and hematologic diseases will support strong long-term market growth.
Segmentation By Drug, Disease Indication, Age Group, Type, Target Pathway, Route of Administration, Distribution Channel, and Region
By Drug * Eculizumab
- Ravulizumab
- Pegcetacoplan
- Iptacopan
- Sutimlimab
- Avacincaptad pegol
- Others
By Disease Indication * Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Generalized Myasthenia Gravis
- Neuromyelitis Optica Spectrum Disorder
- Geographic Atrophy
- Cold Agglutinin Disease
- Others
By Age Group * Pediatric
- Adults
By Type * Branded
- Biosimilar
- Others
By Target Pathway * C5 Inhibitors
- C3 Inhibitors
- C1s Inhibitors
- Factor B Inhibitors
- Factor D Inhibitors
- Others
By Route of Administration * Intravenous
- Subcutaneous
- Intravitreal
- Others
By Distribution Channel * Hospital Pharmacies
- Specialty Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
- Others
By Region * North America (By Drug, Disease Indication, Age Group, Type, Target Pathway, Route of Administration, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Drug, Disease Indication, Age Group, Type, Target Pathway, Route of Administration, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Drug, Disease Indication, Age Group, Type, Target Pathway, Route of Administration, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Drug, Disease Indication, Age Group, Type, Target Pathway, Route of Administration, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug, Disease Indication, Age Group, Type, Target Pathway, Route of Administration, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Challenges
- 3.5. Market Trends
4. Key Insights
- 4.1. Overview of Complement Inhibitors in the Market, 2025
- 4.2. Prevalence of Key Diseases, By Key Regions/ Countries
- 4.3. New Product Launches, By Key Players
- 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
- 4.5. Pipeline Analysis, By Key Players
5. Global Complement Inhibitors Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug
- 5.1.1. Eculizumab
- 5.1.2. Ravulizumab
- 5.1.3. Pegcetacoplan
- 5.1.4. Iptacopan
- 5.1.5. Sutimlimab
- 5.1.6. Avacincaptad pegol
- 5.1.7. Others
- 5.2. Market Analysis, Insights and Forecast - By Disease Indication
- 5.2.1. Paroxysmal Nocturnal Hemoglobinuria (PNH)
- 5.2.2. Atypical Hemolytic Uremic Syndrome (aHUS)
- 5.2.3. Generalized Myasthenia Gravis
- 5.2.4. Neuromyelitis Optica Spectrum Disorder
- 5.2.5. Geographic Atrophy
- 5.2.6. Cold Agglutinin Disease
- 5.2.7. Others
- 5.3. Market Analysis, Insights and Forecast - By Age Group
- 5.3.1. Pediatric
- 5.3.2. Adults
- 5.4. Market Analysis, Insights and Forecast - By Type
- 5.4.1. Branded
- 5.4.2. Biosimilar
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast - By Target Pathway
- 5.5.1. C5 Inhibitors
- 5.5.2. C3 Inhibitors
- 5.5.3. C1s Inhibitors
- 5.5.4. Factor B Inhibitors
- 5.5.5. Factor D Inhibitors
- 5.5.6. Others
- 5.6. Market Analysis, Insights and Forecast - By Route of Administration
- 5.6.1. Intravenous
- 5.6.2. Subcutaneous
- 5.6.3. Intravitreal
- 5.6.4. Others
- 5.7. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.7.1. Hospital Pharmacies
- 5.7.2. Specialty Pharmacies
- 5.7.3. Drug Stores & Retail Pharmacies
- 5.7.4. Online Pharmacies
- 5.7.5. Others
- 5.8. Market Analysis, Insights and Forecast - Region
- 5.8.1. North America
- 5.8.2. Europe
- 5.8.3. Asia Pacific
- 5.8.4. Latin America
- 5.8.5. Middle East & Africa
6. North America Complement Inhibitors Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug
- 6.1.1. Eculizumab
- 6.1.2. Ravulizumab
- 6.1.3. Pegcetacoplan
- 6.1.4. Iptacopan
- 6.1.5. Sutimlimab
- 6.1.6. Avacincaptad pegol
- 6.1.7. Others
- 6.2. Market Analysis, Insights and Forecast - By Disease Indication
- 6.2.1. Paroxysmal Nocturnal Hemoglobinuria (PNH)
- 6.2.2. Atypical Hemolytic Uremic Syndrome (aHUS)
- 6.2.3. Generalized Myasthenia Gravis
- 6.2.4. Neuromyelitis Optica Spectrum Disorder
- 6.2.5. Geographic Atrophy
- 6.2.6. Cold Agglutinin Disease
- 6.2.7. Others
- 6.3. Market Analysis, Insights and Forecast - By Age Group
- 6.3.1. Pediatric
- 6.3.2. Adults
- 6.4. Market Analysis, Insights and Forecast - By Type
- 6.4.1. Branded
- 6.4.2. Biosimilar
- 6.4.3. Others
- 6.5. Market Analysis, Insights and Forecast - By Target Pathway
- 6.5.1. C5 Inhibitors
- 6.5.2. C3 Inhibitors
- 6.5.3. C1s Inhibitors
- 6.5.4. Factor B Inhibitors
- 6.5.5. Factor D Inhibitors
- 6.5.6. Others
- 6.6. Market Analysis, Insights and Forecast - By Route of Administration
- 6.6.1. Intravenous
- 6.6.2. Subcutaneous
- 6.6.3. Intravitreal
- 6.6.4. Others
- 6.7. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.7.1. Hospital Pharmacies
- 6.7.2. Specialty Pharmacies
- 6.7.3. Drug Stores & Retail Pharmacies
- 6.7.4. Online Pharmacies
- 6.7.5. Others
- 6.8. Market Analysis, Insights and Forecast - By Country
- 6.8.1. U.S.
- 6.8.2. Canada
7. Europe Complement Inhibitors Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug
- 7.1.1. Eculizumab
- 7.1.2. Ravulizumab
- 7.1.3. Pegcetacoplan
- 7.1.4. Iptacopan
- 7.1.5. Sutimlimab
- 7.1.6. Avacincaptad pegol
- 7.1.7. Others
- 7.2. Market Analysis, Insights and Forecast - By Disease Indication
- 7.2.1. Paroxysmal Nocturnal Hemoglobinuria (PNH)
- 7.2.2. Atypical Hemolytic Uremic Syndrome (aHUS)
- 7.2.3. Generalized Myasthenia Gravis
- 7.2.4. Neuromyelitis Optica Spectrum Disorder
- 7.2.5. Geographic Atrophy
- 7.2.6. Cold Agglutinin Disease
- 7.2.7. Others
- 7.3. Market Analysis, Insights and Forecast - By Age Group
- 7.3.1. Pediatric
- 7.3.2. Adults
- 7.4. Market Analysis, Insights and Forecast - By Type
- 7.4.1. Branded
- 7.4.2. Biosimilar
- 7.4.3. Others
- 7.5. Market Analysis, Insights and Forecast - By Target Pathway
- 7.5.1. C5 Inhibitors
- 7.5.2. C3 Inhibitors
- 7.5.3. C1s Inhibitors
- 7.5.4. Factor B Inhibitors
- 7.5.5. Factor D Inhibitors
- 7.5.6. Others
- 7.6. Market Analysis, Insights and Forecast - By Route of Administration
- 7.6.1. Intravenous
- 7.6.2. Subcutaneous
- 7.6.3. Intravitreal
- 7.6.4. Others
- 7.7. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.7.1. Hospital Pharmacies
- 7.7.2. Specialty Pharmacies
- 7.7.3. Drug Stores & Retail Pharmacies
- 7.7.4. Online Pharmacies
- 7.7.5. Others
- 7.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.8.1. U.K.
- 7.8.2. Germany
- 7.8.3. France
- 7.8.4. Italy
- 7.8.5. Spain
- 7.8.6. Scandinavia
- 7.8.7. Rest of Europe
8. Asia Pacific Complement Inhibitors Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug
- 8.1.1. Eculizumab
- 8.1.2. Ravulizumab
- 8.1.3. Pegcetacoplan
- 8.1.4. Iptacopan
- 8.1.5. Sutimlimab
- 8.1.6. Avacincaptad pegol
- 8.1.7. Others
- 8.2. Market Analysis, Insights and Forecast - By Disease Indication
- 8.2.1. Paroxysmal Nocturnal Hemoglobinuria (PNH)
- 8.2.2. Atypical Hemolytic Uremic Syndrome (aHUS)
- 8.2.3. Generalized Myasthenia Gravis
- 8.2.4. Neuromyelitis Optica Spectrum Disorder
- 8.2.5. Geographic Atrophy
- 8.2.6. Cold Agglutinin Disease
- 8.2.7. Others
- 8.3. Market Analysis, Insights and Forecast - By Age Group
- 8.3.1. Pediatric
- 8.3.2. Adults
- 8.4. Market Analysis, Insights and Forecast - By Type
- 8.4.1. Branded
- 8.4.2. Biosimilar
- 8.4.3. Others
- 8.5. Market Analysis, Insights and Forecast - By Target Pathway
- 8.5.1. C5 Inhibitors
- 8.5.2. C3 Inhibitors
- 8.5.3. C1s Inhibitors
- 8.5.4. Factor B Inhibitors
- 8.5.5. Factor D Inhibitors
- 8.5.6. Others
- 8.6. Market Analysis, Insights and Forecast - By Route of Administration
- 8.6.1. Intravenous
- 8.6.2. Subcutaneous
- 8.6.3. Intravitreal
- 8.6.4. Others
- 8.7. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.7.1. Hospital Pharmacies
- 8.7.2. Specialty Pharmacies
- 8.7.3. Drug Stores & Retail Pharmacies
- 8.7.4. Online Pharmacies
- 8.7.5. Others
- 8.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.8.1. China
- 8.8.2. Japan
- 8.8.3. India
- 8.8.4. Southeast Asia
- 8.8.5. Australia
- 8.8.6. Rest of Asia Pacific
9. Latin America Complement Inhibitors Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug
- 9.1.1. Eculizumab
- 9.1.2. Ravulizumab
- 9.1.3. Pegcetacoplan
- 9.1.4. Iptacopan
- 9.1.5. Sutimlimab
- 9.1.6. Avacincaptad pegol
- 9.1.7. Others
- 9.2. Market Analysis, Insights and Forecast - By Disease Indication
- 9.2.1. Paroxysmal Nocturnal Hemoglobinuria (PNH)
- 9.2.2. Atypical Hemolytic Uremic Syndrome (aHUS)
- 9.2.3. Generalized Myasthenia Gravis
- 9.2.4. Neuromyelitis Optica Spectrum Disorder
- 9.2.5. Geographic Atrophy
- 9.2.6. Cold Agglutinin Disease
- 9.2.7. Others
- 9.3. Market Analysis, Insights and Forecast - By Age Group
- 9.3.1. Pediatric
- 9.3.2. Adults
- 9.4. Market Analysis, Insights and Forecast - By Type
- 9.4.1. Branded
- 9.4.2. Biosimilar
- 9.4.3. Others
- 9.5. Market Analysis, Insights and Forecast - By Target Pathway
- 9.5.1. C5 Inhibitors
- 9.5.2. C3 Inhibitors
- 9.5.3. C1s Inhibitors
- 9.5.4. Factor B Inhibitors
- 9.5.5. Factor D Inhibitors
- 9.5.6. Others
- 9.6. Market Analysis, Insights and Forecast - By Route of Administration
- 9.6.1. Intravenous
- 9.6.2. Subcutaneous
- 9.6.3. Intravitreal
- 9.6.4. Others
- 9.7. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.7.1. Hospital Pharmacies
- 9.7.2. Specialty Pharmacies
- 9.7.3. Drug Stores & Retail Pharmacies
- 9.7.4. Online Pharmacies
- 9.7.5. Others
- 9.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.8.1. Brazil
- 9.8.2. Mexico
- 9.8.3. Rest of Latin America
10. Middle East & Africa Complement Inhibitors Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Drug
- 10.1.1. Eculizumab
- 10.1.2. Ravulizumab
- 10.1.3. Pegcetacoplan
- 10.1.4. Iptacopan
- 10.1.5. Sutimlimab
- 10.1.6. Avacincaptad pegol
- 10.1.7. Others
- 10.2. Market Analysis, Insights and Forecast - By Disease Indication
- 10.2.1. Paroxysmal Nocturnal Hemoglobinuria (PNH)
- 10.2.2. Atypical Hemolytic Uremic Syndrome (aHUS)
- 10.2.3. Generalized Myasthenia Gravis
- 10.2.4. Neuromyelitis Optica Spectrum Disorder
- 10.2.5. Geographic Atrophy
- 10.2.6. Cold Agglutinin Disease
- 10.2.7. Others
- 10.3. Market Analysis, Insights and Forecast - By Age Group
- 10.3.1. Pediatric
- 10.3.2. Adults
- 10.4. Market Analysis, Insights and Forecast - By Type
- 10.4.1. Branded
- 10.4.2. Biosimilar
- 10.4.3. Others
- 10.5. Market Analysis, Insights and Forecast - By Target Pathway
- 10.5.1. C5 Inhibitors
- 10.5.2. C3 Inhibitors
- 10.5.3. C1s Inhibitors
- 10.5.4. Factor B Inhibitors
- 10.5.5. Factor D Inhibitors
- 10.5.6. Others
- 10.6. Market Analysis, Insights and Forecast - By Route of Administration
- 10.6.1. Intravenous
- 10.6.2. Subcutaneous
- 10.6.3. Intravitreal
- 10.6.4. Others
- 10.7. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.7.1. Hospital Pharmacies
- 10.7.2. Specialty Pharmacies
- 10.7.3. Drug Stores & Retail Pharmacies
- 10.7.4. Online Pharmacies
- 10.7.5. Others
- 10.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.8.1. GCC
- 10.8.2. South Africa
- 10.8.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Alexion Pharmaceuticals, Inc. (AstraZeneca Rare Disease)
- 11.2.2. Novartis AG
- 11.2.3. F. Hoffmann-La Roche Ltd
- 11.2.4. Apellis Pharmaceuticals, Inc.
- 11.2.5. UCB S.A.
- 11.2.6. Amgen Inc.
- 11.2.7. Regeneron Pharmaceuticals, Inc.
- 11.2.8. Omeros Corporation
- 11.2.9. Annexon, Inc.
- 11.2.10. BioCryst Pharmaceuticals, Inc.
